Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
72.54
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
64
Open
72.54
Bid (Size)
71.75 (2)
Ask (Size)
73.00 (1)
Prev. Close
72.54
Today's Range
72.54 - 72.54
52wk Range
55.02 - 98.40
Shares Outstanding
47,190,970
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
Performance
YTD
-5.87%
-5.87%
1 Month
-10.60%
-10.60%
3 Month
-0.90%
-0.90%
6 Month
-2.72%
-2.72%
1 Year
+14.78%
+14.78%
More News
Read More
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Via
InvestorPlace
Earnings Outlook For Axsome Therapeutics
February 19, 2024
Via
Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
February 06, 2024
Via
Benzinga
The Analyst Landscape: 6 Takes On Axsome Therapeutics
January 16, 2024
Via
Benzinga
3 Biotech Stocks to Buy and Hold for the Next 10 Years
February 26, 2024
Via
The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
February 20, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
February 20, 2024
Via
Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
February 20, 2024
Via
Investor's Business Daily
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 20, 2024
February 20, 2024
Via
Benzinga
2 Stocks That Could Double Your Money in 5 Years
February 08, 2024
Via
The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
Via
Benzinga
5 medical stocks growing earnings by triple digits
February 06, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
January 26, 2024
Via
Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
January 25, 2024
Via
Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Via
Investor's Business Daily
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 23, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
January 03, 2024
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
January 02, 2024
Via
The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
January 01, 2024
Via
The Motley Fool
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
December 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.